9.97
+2.68%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Xinjiang Bai Hua Cun Pharma Tech Co
Its shares trade on Shanghai under the ticker 600721.SS. It has been listed since 26 June 1996. In the fiscal year to 31 December 2025, it reported revenue of CN¥387.6m and net income of CN¥40.7m. At that date it held total assets of CN¥1.10bn and shareholders' equity of CN¥801.8m.
Xinjiang Baihuacun Pharam Tech Co., Ltd. provides medical research and development services as a contract research organization (CRO). The company is headquartered in Urumqi, Xinjiang. The firm's main business is the research and development, registration and application of small molecule chemicals and the development of peptide drugs. The firm is engaged in the early discovery and screening of new drugs, drug clinical trials, biological sample analysis, medicine testing services, active pharmaceutical ingredient (API) and intermediate supply. The firm is also engaged in leasing and property services. The firm mainly conducts business within the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Materials
- Industry
- Metals & Mining
- Listed since
- 26 Jun 1996
- Employees
- 731
- Website
- xjbhc.net ↗
Leadership
Pay as last reported
- Ms. Caihong ZhengChairman of the Board, since 2017
- Ms. Ziyun CaiChief Financial Officer
- Mr. Hui HuangRotating General Manager, Director, since 2022
- Mr. Zhengtian LuExecutive Deputy General Manager, Director, since 2007CN¥248,700
- Mr. Yan XiaDeputy General Manager, Director, since 2023
- Ms. Qinqin ZhaoSecretary of the Board
- Chunzhi DaiDirector, since 2008
- Wensheng GuoDirector
- Mr. Tiejun HouDirectorCN¥414,900
- Mr. Bo MaDirectorCN¥58,100
- Mr. Jianbin SunDirector
- Ms. Li GuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Xinjiang Bai Hua Cun Pharma Tech employs 731 full-time employees for medical R&D services.
- The company focuses on small molecule chemicals and peptide drug development in the Metals & Mining sector.
- Xinjiang Bai Hua Cun Pharam Tech provides API and intermediate supply for pharmaceutical applications.
Weaknesses
- The firm operates primarily within the domestic market of China with limited international presence.
- Xinjiang Bai Hua Cun Pharam Tech's business is concentrated in the Metals & Mining industry segment.
- The company's leasing and property services are a minor part of its overall operations.
Opportunities
- Xinjiang Bai Hua Cun Pharam Tech can expand its small molecule chemical research in the domestic market.
- The firm may grow its peptide drug development segment within the Metals & Mining sector.
- Xinjiang Bai Hua Cun Pharam Tech could increase API and intermediate supply services for pharmaceutical companies.
Threats
- The domestic market in China may face regulatory changes affecting pharmaceutical R&D.
- Xinjiang Bai Hua Cun Pharam Tech's focus on Metals & Mining could limit diversification opportunities.
- The company's reliance on domestic market operations poses a risk from economic fluctuations in China.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.